IP Verse

Engager Cells For Immunotherapy - EP2964675

The patent EP2964675 was granted to Baylor College OF Medicine on Jun 20, 2018. The application was originally filed on Mar 5, 2014 under application number EP14714473A. The patent is currently recorded with a legal status of "Revoked".

EP2964675

BAYLOR COLLEGE OF MEDICINE
Application Number
EP14714473A
Filing Date
Mar 5, 2014
Status
Revoked
Feb 14, 2020
Grant Date
Jun 20, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SCHLICHMar 19, 2019SCHLICH -

Patent Citations (13) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS4683202
DESCRIPTIONUS4797368
DESCRIPTIONUS5139941
DESCRIPTIONUS5928906
DESCRIPTIONUS5994136
DESCRIPTIONUS6013516
DESCRIPTIONWO9420627
DESCRIPTIONWO9954440
INTERNATIONAL-SEARCH-REPORTUS2013071414
INTERNATIONAL-SEARCH-REPORTWO2009091826
OPPOSITIONUS2005107869
OPPOSITIONUS2008004413
OPPOSITIONWO2014011988

Non-Patent Literature (NPL) Citations (9) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, The Human Portein atlas, URL: https://www.proteinatlas.orq/ENSG00000177455- CD 19/patholoqy-
OPPOSITION- HAMMOND S. A. et al., "Selective targeting and potent control of tumor growth using an EphA2/CD3-bispecific single-chain antibody construct", Cancer Res., (20070000), vol. 67, no. 8, pages 3927 - 3935, XP002578205-
OPPOSITION- "RNA and protein expressin summary", The Human Portein atlas, pages 1 - 3, URL: https://www.proteinatlas.orq/ENSG00000177455- CD 19/tissue-
OPPOSITION- FOURNIER P. et al., "Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future", BioDrugs, (20121221), vol. 27, no. 1, pages 35 - 53, XP008170163
OPPOSITION- FRANKEL S. R. et al., "Targeting T cells to tumor cells using bispecific antibodies", Current Opinion in Chemical Biology, (20130000), vol. 17, no. 3, pages 385 - 392, XP002787546
OPPOSITION- MOLHOJ M. et al., "CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis", Molecular Immunology, (20070000), vol. 44, no. 8, pages 1935 - 1 943, XP005792730
OPPOSITION- COMPTE M. et al., "Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA × anti-CD3 diabodies from lentivirally transduced human lymphocytes", Cancer Gene Therapy, (20070000), vol. 14, no. 4, pages 380 - 388, XP055388560
OPPOSITION- VELASQUEZ M. P. et al., "T cells expressing CD19-specific Engager Molecules for the Immunotherapy of CD19-positive Malignancies", Nature Scientific Reports, (20160000), vol. 6, pages 1 - 11, XP055582695
OPPOSITION- WYKOSKY J. et al., "The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting", Mol Cancer Res., (20080000), vol. 6, no. 12, pages 1795 - 1806, XP009157971

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents